USP Building Risk Model To Assess Supply Chain Vulnerabilities And Anticipate Drug Shortages
Model Mines Reference Standards Data
Executive Summary
The USP is developing a risk model to assess whether pharmaceutical supply chains are strong or weak based on demand for reference standards.
You may also be interested in...
Hospitals Struggle To Supply COVID-19 Teams With The Medicines They Need
Vials arrive in fits and starts, often in wrong sizes, as allocation quotas, quality issues and difficulty anticipating surges wreak havoc in pharmaceutical supply chain.
China’s Global Pharma Supply Chain Operations Resuming In Wake Of Outbreak, USP Says
USP reference standard sales showed slow resumption of API manufacturing in China and less-than-expected API use in India.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”